WAYNE, P.A., and UTRECHT, NETHERLANDS — June 16, 2025 — NanoCell Therapeutics, Inc. (“NanoCell”), a biotechnology company developing a non-viral, DNA-based in vivo gene therapy platform, today announced the successful closing of a seed-extension financing round, with participation from The Institute for Follicular Lymphoma Innovation (“IFLI”), a leading non-profit organization dedicated exclusively to funding innovative follicular lymphoma research and development.
The funding will accelerate IND-enabling development of NanoCell’s lead clinical candidate, NCTX-01, a dual-CAR CD19/CD22 in vivo CAR-T therapy for B cell malignancies. NanoCell will use the capital to further evaluate NCTX-01’s safety, efficacy and durability in treating aggressive forms of lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma.
“IFLI’s support enables us to accelerate NCTX-01 through preclinical development to clinical development,” said Maurits Geerlings, MD, President & Chief Executive Officer of NanoCell. “This partnership provides crucial resources to generate the preclinical data package needed for regulatory discussions. IFLI shares our belief that non-viral in vivo approaches have transformative potential to address significant unmet medical needs for patients who currently have limited treatment options.
“NanoCell’s innovative platform offers a novel approach to treating both follicular lymphoma and diffuse large B-cell lymphoma and could potentially overcome many of the current barriers that limit patient access to CAR-T therapies,” said Michel Azoulay, MD, MBA, Chief Medical Officer at IFLI. “Supporting this program aligns with IFLI’s mission to accelerate innovative therapies that can make a meaningful difference in the lives of patients.”
About NanoCell Therapeutics, Inc.
NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. The company is dedicated to pioneering transformative in-vivo cell engineering through its non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases. By leveraging a proprietary targeted lipid nanoparticle delivery platform, NanoCell is addressing key limitations of traditional CAR-T therapies, including high manufacturing costs, complex logistics and limited accessibility. The company’s approach aims to deliver one-time, off-the-shelf treatments for cancer and autoimmune diseases, with the potential to reach broader patient populations.
About the Institute for Follicular Lymphoma Innovation (IFLI)
The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research and for more information on IFLI, visit www.i-fli.org.
Contact:
Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com